

April 21, 2009



Neurology Snapshot: Alzheimer's Disease

Event: American Academy of Neurology, April 25-May 2, 2009



AD Market Leaders

Pfizer (NYSE:PFE)/**Medivation** (NASDAQ:MDVN): Dimebon- improves mitochondrial function

[Medivation's Dimebon has probable effect on oxidative stress pathway, investigator and physicians say \(Pharmawire\)](#)

[Medivation: some experts skeptical of Dimebon's chances of attaining FDA approval \(Pharmawire\)](#)

[Medivation: Dimebon's efficacy in Alzheimer's unlikely to be caused by effect on histamine receptors - analysis \(Pharmawire\)](#)

[Medivation considering combination studies of Alzheimer's candidate dimebon, CEO says; skepticism remains regarding potential success of a Phase III study \(Pharmawire\)](#)

[Pfizer makes Alzheimer's disease a priority "invest to win" area, company says; TauRx currently evaluating strategic options \(Pharmawire\)](#)

[Pfizer actively moving into next generation Alzheimer's research, executive says; industry seeks alternative options to amyloid hypothesis \(Pharmawire\)](#)

Pfizer (NYSE:PFE)/**Eisai** (OTC:ESALY): Aricept- reversible inhibitor of the enzyme acetylcholinesterase to balance levels of dopamine and acetylcholine.

GSK (NYSE:GSK): Avandia XR- PPAR gamma agonist & GSK-239512- histamine H3 antagonist (dementia)

Wyeth (NYSE:WYE)/ **Elan** (NYSE:ELN): Bapineuzumab- monoclonal antibody to beta amyloid

[Wyeth's bapineuzumab and other failed anti-amyloid agents may show efficacy if FDA creates pathway to conduct pre-symptomatic AD trials - analysis \(Pharmawire\)](#)

[Wyeth/Elan's Alzheimer's candidate bapineuzumab faces potential Phase III hurdles - analysis \(Pharmawire\)](#)

[Wyeth/Elan's Alzheimer's drug bapineuzumab faces significant hurdles, both from a clinical development and reimbursement standpoint, physicians say \(Pharmawire\)](#)

[Wyeth/Elan's bapineuzumab holds promise for treatment of Alzheimer's, but physicians remain wary due to history of setbacks with disease modifying agents \(Pharmawire\)](#)

Eli Lilly (NYSE:LLY): LY450139- gamma secretase inhibitor

[Eli Lilly's Phase III Alzheimer's drug LY450139 shows plaque reduction, but it may not translate into clinical improvement, physicians say \(Pharmawire\)](#)

[Eli Lilly's Alzheimer's drug has delivery advantage over competition, but has yet to pass safety hurdles \(Pharmawire\)](#)

Baxter (NYSE:BAX): Gammagard- Immune Globulin Intravenous (Human)

[Baxter confident in Gammagard Alzheimer's efficacy despite questions about beta amyloid theory, safety warnings, executive, investigators say \(Pharmawire\)](#)

[Baxter's Gammagard \(IVIG\) for treatment of Alzheimer's faces significant price and supply hurdles, physicians say \(Pharmawire\)](#)

Forest Laboratories (NYSE:FRX): Namenda- NMDA glutamate receptor antagonist



Unpartnered Targets in Development

Anavex Life Sciences Corp (OTC:AVXL): Market cap USD 45.9m

Anavex 1-41- alleviates amyloid- β induced oxidative stress and has anti-apoptotic properties

[Anavex believes that oxidative stress, not amyloid-beta, is the cause of Alzheimer's; seeking partners for early-stage compound, executives say \(Pharmawire\)](#)

Prana Biotechnology (NASDAQ:PRAN): Market cap USD 32.4m

PBT2- inhibits oligomer formation, disaggregates plaques, neutralizes A β toxicity

[Prana currently in talks to partner Alzheimer's agent PBT2, but physicians caution on potential off-target effects of metal chelation \(Pharmawire\)](#)

Epix Pharmaceuticals (NASDAQ:EPIX): Market cap USD 14.3m

PRX-0314- partial 5-HT₄ receptor agonist

[EPIX begins second Phase 2b trial to evaluate PRX-03140 in treatment of Alzheimer's disease](#)

Ceregene: Received USD 5.4m grant from NIH November 2008

CERE-110- ex vivo gene delivery designed to reduce cholinergic cell loss

[Ceregene in active partnership talks with large pharma for two drug candidates, CEO says \(Pharmawire\)](#)

TorreyPines Therapeutics (NASDAQ:TPTX): Market cap USD 2.78m

NGX-267- a partial muscarinic receptor agonist with functionally specific M1 receptor activity

[TorreyPines currently seeking partners for gamma-secretase modulator program, CEO says \(Pharmawire\)](#)

TauRx Therapeutics Ltd.: Founded by Venture Capitalist in 2002

Rember- Tau aggregation inhibitor

[TauRx's Rember looks promising, but data still has to be replicated in larger studies, CEO says \(Pharmawire\)](#)

[TauRx in discussions with advisors over four potential financing options, plans to raise USD 200m, CEO says \(Pharmawire\)](#)